

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61L 33/00	A1	(11) International Publication Number: WO 91/19521 (43) International Publication Date: 26 December 1991 (26.12.91)
<p>(21) International Application Number: PCT/NL91/00103</p> <p>(22) International Filing Date: 19 June 1991 (19.06.91)</p> <p>(30) Priority data: 9001387 19 June 1990 (19.06.90) NL</p> <p>(71) Applicant (for all designated States except US): HOLLAND BIOMATERIALS GROUP B.V. [NL/NL]; Drienerlolaan 5, NL-7522 NB Enschede (NL).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): ENGBERS, Gerardus, Henricus, Maria [NL/NL]; Vlier 3, NL-7577 AP Oldenzaal (NL). FEIJEN, Jan [NL/NL]; Oude Grensweg 96, NL-7552 GD Hengelo (NL).</p> <p>(74) Agent: SMULDERS, Th., A., H., J.; Verenigde Octrooibureaux, Nieuwe Parklaan 107, NL-2587 BP The Hague (NL).</p>		<p>(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. In English translation (filed in Dutch).</i></p>
<p>(54) Title: METHOD OF MODIFYING THE PROPERTIES OF A SUBSTRATE SURFACE BY COVALENT BONDING OF A COMPOUND TO THE SURFACE, AND MEMBRANE MODIFIED ACCORDING TO THIS METHOD</p> <p>(57) Abstract</p> <p>A method of modifying the properties of a surface of a substrate by covalent bonding of a compound to the surface, the compound comprising one or more functional groups which are all or partly activated by a reagent in a solvent-containing first solution, whereafter the activated compound is bonded to a functional substrate surface in a solvent-containing second solution.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

Title: Method of modifying the properties of a substrate surface by covalent bonding of a compound to the surface, and membrane modified according to this method.

The invention relates to a method of modifying a substrate surface by covalent bonding of a compound to the substrate surface, so that the properties of the substrate surface with regard to the interaction of the substrate surface with
5 chemical compounds and/or cells in particular environments are modified.

An example of such a substrate and method is known from Dutch Patent Application No. 8701337, according to which a physiologically active compound is bonded to the substrate
10 surface via a polyacid, which changes the properties of the substrate surface, when in contact with blood, in such a way that less or no coagulation occurs on the substrate surface.

The object of the invention is to obtain a new, simple method with which the properties of substrate surfaces,
15 preferably substrate surfaces with a suitable functionality, can be modified. The existing methods typically start from activating the substrate surface, followed by immobilizing a particular compound on the activated substrate surface. When such methods are used on specific substrate surfaces there is
20 a chance of undesired modification of the substrate surface. In the method according to the invention, the order is reversed, i.e. first the compound is activated and then it is bonded to the substrate surface. The advantage thereof is that the substrate surface is not available to the reagent used for
25 activating the compound.

The invention is characterized in that the compound to be bonded contains one or more functional groups, for example, hydroxyl- and/or carboxyl- and/or amino groups; the compound is activated by means of a reagent in a solvent suitable for
30 this purpose; and via a one-step procedure the activated compound is bonded covalently to a substrate surface with a suitable functionality. Preferably, in the method according to

- not
plasma

the invention, a substrate surface is selected which comprises functional groups necessary for the covalent bonding of the activated compound, preferably hydroxyl- and/or carboxyl- and/or amino groups. To immobilize the compound on the substrate surface, preferably a bifunctional reagent is used, more preferably a carbonylating reagent of the general structural formula $R_1-(CO)-R_2$, wherein R_1 and R_2 represent groups which can easily be separated. Examples of such a reagent are 1,1'-carbonyl diimidazole or 1,1-carbonyldi-1,2,4-triazole. The choice of the reagent is determined *inter alia* by the nature of the functional group(s) of the compound and of the substrate and by the choice of the solvents to be used.

Apart from the feature that the compound contains one or more functional groups, the compound can be any compound which, after immobilization, changes the properties of the substrate surface involved, when in contact with a particular environment. Examples are compounds which, after immobilization, increase the biocompatibility of the substrate surface, for instance heparin.

The method is particularly suitable when the compound is a polyelectrolyte or a polyelectrolyte-containing compound having more than one functional group, for instance heparin. With these compounds, during activation of the compound, no cross-linking of the compound occurs, which adds an extra advantage to the method.

The compound is activated in a solvent suitable for activation, which solvent is not reactive with respect to the bifunctional reagent and the activated compound. The compound is immobilized in a solvent suitable for the immobilization of a sufficient amount of the compound to be immobilized. Examples of suitable solvents for activation in the case where the bifunctional reagent is a carbonylating reagent of the general structural formula $R_1-(CO)-R_2$, for example, 1,1'-carbonyl diimidazole or 1,1-carbonyl-1,2,4-triazole, are dioxane, tetrahydrofuran, acetone, formamide, dimethyl formamide and dichloromethane. The choice of the solvent

during activation of the compound is also based on the solubility of the compound. The choice of the solvent during immobilization is also determined by the interaction of the substrate surface with the solvent and by the solubility of the activated compound in the solvent. Mixtures of several solvents can also be used.

By way of example, the compound can be activated in a solution with a solvent of an organic nature, which solution, after the required reaction time, is added to the substrate surface which is in an aqueous environment.

As regards the compound, it may be necessary to modify it in such a way that its solubility in the selected solvent is increased. If the compound is a polyelectrolyte, this can be done by an appropriate choice of the counterion.

When a substrate surface to be modified does not have the required reactive groups it is possible to provide the surface in question with such groups beforehand.

In order to optimize the interaction of the compound after immobilization with components from the environment to which the substrate is exposed, it is possible to provide the surface beforehand with so-called "spacer" molecules, which increase the distance between the substrate surface and the compound. An example of a suitable spacer molecule is a functional poly(ethylene oxide)-containing molecule which, after bonding to the substrate surface, contains one or more functional groups, preferably a hydroxyl- and/or carboxyl- and/or amino group(s).

In addition to the advantage realized by the invention, namely obtaining a substrate surface with modified properties, a further advantage is that by first activating the compound there is no bifunctional reagent available during the immobilization step to react with the substrate surface. This makes the method advantageously suitable for modifying hydrophilic substrates, of which only the properties of the substrate surface change upon modification according to the

method. Examples of such hydrophilic substrates are cellulose-based membranes and hydrogels.

The method also has the advantage that when the compound to be bonded is a polyelectrolyte-containing compound having
5 more groups per molecule which are reactive with respect to the bifunctional reagent, for example heparin, cross-linking of the polyelectrolyte does not occur during the activation of said polyelectrolyte. The advantage is that the activity of the compound is retained after immobilization. Furthermore,
10 the method is so simple that the surface modification with the activated compound can be carried out as a one-step procedure.

The invention also relates to a membrane having a surface modified in accordance with the method of the invention, preferably a cellulose membrane wherein the compound to be
15 activated is heparin or a heparin-analogue.

In accordance with a further elaboration of the invention, hydroxyl- and/or carboxyl groups of the heparin are first activated with a bifunctional reagent, preferably a carbonylating reagent of the general structural formula
20 $R_1-(CO)-R_2$, more preferably 1,1'-carbonyl diimidazole or 1,1-carbonyl-1,2,4-triazole. The activation takes place in a solvent which is not reactive with respect to the bifunctional reagent and the activated heparin, for example formamide. During this activation no cross-linking of the heparin occurs.
25 Subsequently, the membrane is incubated in the solution of the activated heparin. After rinsing and drying the heparinized membrane is obtained.

In addition to the advantage accomplished by the invention, namely a strong improvement of the blood
30 compatibility of the membrane, a further advantage is that by pre-activating the heparin with the reagent, during the immobilization step the reagent is not available for cross-linking the membrane, so that the permeability of the membrane involved is not affected by cross-linking of the membrane by
35 the bifunctional reagent.

EXAMPLE

Heparin sodium salt is converted into heparin-benzyl trimethyl ammonium salt via an ion-exchange procedure in order to increase the solubility of heparin in organic solvents.

5 Subsequently, the heparin salt is dissolved in formamide (0.25 g.ml⁻¹) to which carbonyl diimidazole (CDI) is added until a heparin/CDI ratio (w/w) of 8.5 has been reached. After stirring for half an hour at room temperature, a cellulose membrane is added whereafter the reaction mixture is regularly

10 homogenized for 48 hours. Thereafter, the membrane is rinsed with formamide, water and a NaCl solution and subsequently incubated in a glycerol solution and dried.

The heparinized membrane has a typical heparin surface concentration of about 50 µg.cm⁻². This amount can be varied

15 controllably by adjusting the heparin concentration in the reaction mixture (see Fig. 1) The heparinized membrane has the same permeability to urea as the non-modified membrane. The blood compatibility of the membrane has been highly improved by the heparinization procedure. In comparison with

20 citrate plasma which is incubated in non-modified membranes, citrate plasma which is incubated in the heparinized membranes shows a prolonged coagulation time (see Fig. 2). Further, heparinized membranes, unlike non-modified membranes, hardly, if at all, give rise to complement activation when they are

25 contacted with blood (see Fig. 3).

CLAIMS

1. A method of modifying the properties of a surface of a substrate by covalent bonding of a compound to the surface, characterized in that the compound contains one or more functional groups which are all or partly activated by a reagent in a solvent-containing first solution, whereafter the activated compound is bonded to a functional substrate surface in a solvent-containing second solution.
2. A method as claimed in claim 1, characterized in that the functional reagent is a bifunctional reagent.
3. A method as claimed in claim 2, characterized in that the bifunctional reagent is a carbonylating reagent.
4. A method as claimed in claim 3, characterized in that the carbonylating reagent has the structural formula $R_1-(CO)-R_2$, wherein R_1 and R_2 represent groups which can easily be separated.
5. A method as claimed in claim 4, characterized in that the carbonylating reagent is 1,1'-carbonyl diimidazole.
6. A method as claimed in claim 4, characterized in that the carbonylating reagent is 1,1'-carbonyl-1,2,4-triazole.
7. A method as claimed in claims 1-6, characterized in that the functional groups of the compound are carboxyl- and/or hydroxyl- and/or amino groups.
8. A method as claimed in claim 1, characterized in that the functional substrate surface comprises hydroxyl- and/or carboxyl- and/or amino groups.
9. A method as claimed in claims 1-8, characterized in that the compound is a physiologically active compound which, after immobilization on the substrate surface, increases the biocompatibility of the surface.
10. A method as claimed in claim 9, characterized in that the physiologically active compound is heparin or a heparin-analogue.

11. A method as claimed in claim 1, characterized in that the solvent of the solution for activating the compound is of an organic nature.
12. A method as claimed in claim 11, characterized in that the solvent is dioxane, tetrahydrofuran, dimethylformamide, tetrahydrofuran, dimethylformamide, acetone, formamide or dichloroethane.
13. A method as claimed in claims 11-12, characterized in that the solvent is a mixture of a plurality of solvents.
14. A method as claimed in claim 1, characterized in that the substrate surface is cellulose or a cellulose derivative.
15. A method as claimed in claim 1 and claim 8, characterized in that the substrate surface comprises a hydrogel.
16. A method as claimed in claim 1, characterized in that the activated compound is bonded to the substrate surface via a spacer molecule.
17. A method as claimed in claim 16, characterized in that a poly(ethylene oxide)-containing molecule having two or more functional groups is used as the spacer molecule.
18. A method as claimed in claim 17, characterized in that the functional groups are hydroxyl- and/or carboxyl- and/or amino groups.
19. A membrane comprising a surface with modified properties, a compound having been immobilized on the surface via a covalent bond, characterized in that the compound has been immobilized according to the method as claimed in claims 1-18.
20. A membrane as claimed in claim 19, characterized in that the membrane is made of cellulose.
21. A membrane as claimed in claim 19, characterized in that the membrane is made of a cellulose derivative.
22. A membrane as claimed in claims 19-21, characterized in that the compound is a physiologically active compound.
23. A membrane as claimed in claim 22, characterized in that the physiologically active compound is a compound which increases the blood compatibility of the membrane.

24. A membrane as claimed in claim 23, characterized in that the physiologically active compound is a compound comprising a polyelectrolyte.

25. A membrane as claimed in claim 24, characterized in that
5 the physiologically active compound is heparin.

26. A membrane as claimed in claim 24, characterized in that the physiologically active compound is fractionated heparin.


27. A membrane as claimed in claim 24, characterized in that the physiologically active compound is a chemically modified
10 heparin.

28. A membrane as claimed in claim 25, characterized in that the heparin is a heparin having a low molecular weight.

29. A membrane as claimed in claim 25, characterized in that the heparin has an increased activity.


15 30. A membrane as claimed in claim 24, characterized in that the physiologically active compound is a heparin-analogue.

1/2



Influence of the heparin concentration of the reaction solution on the amount of immobilized heparin.

FIG. 1




Recalcification time of plasma in contact with heparinized (approx. $25 \text{ mg}/\text{cm}^2$) and non heparinized Cuprophane®.

FIG. 2

2/2

C3a-generation (ng/ml)



C3a generation as a result of blood-membrane contact by heparinized (approx. $50 \mu\text{g}/\text{cm}^2$) and non heparinized Cuprophan® as a function of incubation time.

FIG. 3

INTERNATIONAL SEARCH REPORT

PCT/NL 91/00103

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC <div style="display: flex; justify-content: space-between; width: 80%;"> Int.Cl. 5 A61L33/00 </div>		
II. FIELDS SEARCHED <div style="display: flex; justify-content: space-between; width: 80%;"> Minimum Documentation Searched⁷ Classification Symbols </div> <div style="display: flex; justify-content: space-between; width: 80%;"> Int.Cl. 5 A61L </div>		
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,46 828 (TEIJIN) March 10, 1982 see page 3, line 5 see page 6, line 25 - line 33 see page 8, line 35 - page 9, line 14 see page 11, line 9 - line 23 see page 16, line 1 - line 15 ---	1
A	EP,A,336 964 (TERUMO K.K.) October 18, 1989 see page 7 - page 9 see claims ---	1-30
A	EP,A,294 905 (SENTRON) December 14, 1988 & NL,A,8 701 337 (SENTRON) January 2, 1989 cited in the application ---	1-30
A	EP,A,86 186 (O.LARM) August 17, 1983 ---	
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold; margin-top: 10px;">03 OCTOBER 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold; margin-top: 10px;">16.10.91</div>	
International Searching Authority <div style="text-align: center; font-weight: bold; margin-top: 10px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; font-weight: bold; margin-top: 10px;">COUSINS- VAN STEEN</div> <div style="text-align: right; margin-top: -20px;"> </div>	

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

NL 9100103
SA 48962

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03/10/91

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-46828	10-03-82	None	
EP-A-336964	18-10-89	JP-A- 63139901 JP-A- 63154180 WO-A- 8804183	11-06-88 27-06-88 16-06-88
EP-A-294905	14-12-88	NL-A- 8701337 JP-A- 2131769	02-01-89 21-05-90
EP-A-86186	17-08-83	AU-B- 562784 AU-A- 1441583 CA-A- 1227480 JP-A- 58147404 SE-A- 8200751 US-A- 4810784 US-A- 4613665	18-06-87 15-11-84 29-09-87 02-09-83 10-08-83 07-03-89 23-09-86

EPO FORM PCT/79

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82